| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-06-11 | ToleraCyte™ (programmed CD34+ immuno-regulatory cell product) | preclinical | Fate Therapeutics (USA - CA) | Autoimmune diseases | |
| 2016-06-10 | Kalydeco® (ivacaftor) | cystic fibrosis | Vertex Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases | |
| 2016-06-10 | CHS-0214 (investigational etanercept biosimilar) | rheumatoid arthritis | 3 | Coherus BioSciences (USA - CA) Daiichi Sankyo (Japan) Baxalta (USA - IL) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-06-09 | baricitinib (LY3009104) | rheumatoid arthritis | 3 | Eli Lilly (USA - IN) Incyte Corporation (USA - DE) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-06-09 | olaratumab | advanced soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery | 1b/2 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2016-06-09 | ALN-TTRsc02 | transthyretin-mediated amyloidosis (ATTR amyloidosis) | 1 | Alnylam Pharmaceuticals (USA - MA) | Rare diseases - Genetic diseases |
| 2016-06-08 | M923, a biosimilar version of Humira® (adalimumab) | 1 | Momenta Pharmaceuticals (USA - MA) Baxalta (USA - IL) | Autoimmune diseases – Inflammatory diseases | |
| 2016-06-08 | AMG 334 (erenumab) | prevention of episodic migraine | 2 | Amgen (USA - CA) Novartis (Switzerland) | CNS diseases |
| 2016-06-07 | ublituximab and TGR-1202 | diffuse large B-cell lymphoma (DLBCL) | 2b | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2016-06-07 | opicinumab (anti-LINGO-1 - BIIB033) | relapsing multiple sclerosis | 2 | Biogen (USA - MA) | Neurodegenerative diseases |
| 2016-06-07 | ICT-107 with maintenance temozolomide | glioblastoma | 3 | ImmunoCellular Therapeutics (USA - CA) | Cancer - Oncology - Rare diseases |
| 2016-06-07 | BGB324 and erlotinib | non-small cell lung cancer | 1-2 | BergenBio (Norway) | Cancer - Oncology |
| 2016-06-07 | IFX-1 | patients undergoing complex cardiac surgery | 2 | InflaRx (Germany) | Cardiovascular diseases |
| 2016-06-06 | sacituzumab govitecan - IMMU-132 | metastatic non-small-cell lung cancer (NSCLC), | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-06-06 | sacituzumab govitecan - IMMU-132 | metastatic small-cell lung cancer (SCLC) | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-06-06 | aramchol | NASH (non-alcoholic steatohepatitis) | 2b | Galmed Pharmaceuticals (Israel) | Hepatic diseases - Liver diseases |
| 2016-06-06 | MOR202 (antiCD38 antibody) | relapsed or refractory multiple myeloma | 1-2a | MorphoSys (Germany) | Cancer - Oncology - Rare diseases |
| 2016-06-06 | dupilumab | moderate-to-severe atopic dermatitis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Dermatological diseases - Inflammatory diseases |
| 2016-06-06 | MSB0010718C (avelumab) | metastatic Merkel cell carcinoma | 2 | Merck Serono (Germany) Pfizer (USA - NY) | Cancer - Oncology |
| 2016-06-06 | seliciclib and sapacitabine | advanced solid tumors | 1 | Cyclacel Pharmaceuticals (USA - NJ) | Cancer - Oncology |
